AQEMIA
Inventing New Drugs at Scale with AI and Physics
Paris, France · Founded 2019 · $144.3M raised
- Headquarters
- Paris
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- aqemia.com
- Total Funding
- $144.3M
- Last Round
- $7.4M GrantApr 2025
- Rounds
- 6
About
AQEMIA is a Paris-based pharmatech company founded in 2019 that combines atomic-scale physics algorithms and generative AI to accelerate drug discovery. Its platform, rooted in over 12 years of academic research at CNRS and École Normale Supérieure, eliminates the need for experimental training data to predict drug-target affinities. AQEMIA runs internal and partnered programs in oncology and other high-need therapeutic areas, with collaborations including Sanofi and Servier.
Summary
AQEMIA is an Artificial Intelligence company based in Paris, France, founded in 2019. It has raised $144.3M in total across 6 rounds, most recently a $7.4M Grant round in Apr 2025. Investors include Elaia, Eurazeo and Bpifrance.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2025
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company